Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Menveo powder and solution for solution for injection
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Meningococcal group a, c, w135 and y conjugate vaccine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
Menveo is a vaccine that is used for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to a bacterium named Neisseria meningitidis serogroups A, C, W-135 and Y, to prevent invasive disease. The vaccine works by causing your body to make its own protection (antibodies) against these bacteria. Neisseria meningitidis serogroup A, C, W-135 and Y bacteria can cause serious and sometimes life-threatening infections such as meningitis and sepsis (blood poisoning). Menveo cannot cause bacterial meningitis. This vaccine contains a protein (called CRM197) from the bacteria that cause diphtheria. Menveo does not protect against diphtheria. This means that you (or your child) should receive other vaccines to protect against diphtheria when these are due or when advised by your doctor. 2.
What you need to know before you or your child are given Menveo
Do not use Menveo if you or your child has: ever had an allergic reaction to the active substances or any of the other ingredients of this vaccine (listed in section 6) ever had an allergic reaction to diphtheria toxoid (a substance used in a number of other vaccines) an illness with high fever. However, a mild fever or upper respiratory infection (for example cold) itself is not a reason to delay vaccination.
1
Warnings and precautions: Talk to your doctor or nurse before you or your child are given Menveo if you or your child: have a weakened immune system. Little is known about the effectiveness of Menveo when administered to individuals with weakened immunity due to the use of immunosuppressive medications, or HIV infection, and other possible causes. It is possible that the effectiveness of Menveo could be reduced in such individuals. have haemophilia or any other problem that may stop your blood from clotting properly, such as persons receiving blood thinners (anticoagulants). receive treatment that blocks the part of the immune system known as complement activation, such as eculizumab. Even if you have been vaccinated with Menveo you remain at increased risk of disease caused by the Neisseria meningitidis groups A, C, W-135 and Y bacteria. Fainting, feeling faint or other stress-related reactions can occur as a response to any needle injection. Tell your doctor or nurse if you have experienced this kind of reaction previously. This vaccine can only protect against meningococcal group A, C, W-135, and Y bacteria. It cannot protect against other types of meningococcal bacteria other than groups A, C, W-135 and Y, or against other causes of meningitis and sepsis (blood poisoning). As with any vaccine, Menveo may not fully protect 100% of those who get the vaccine. If you or your child received a dose of Menveo more than one year ago and remains at particular risk of exposure to meningococcal group A bacteria, consideration may be given to administering a booster dose to maintain protection. Your doctor will advise you if and when you should receive a booster dose. Other medicines and Menveo Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. Menveo may be given at the same time as other vaccinations but any other injected vaccines should preferably be given into a different arm from the site of the Menveo injection. These include the following vaccines: tetanus, reduced diphtheria and acellular pertussis (Tdap), human papillomavirus (HPV), yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, rabies, hepatitis A and B and meningococcal group B (Bexsero). Menveo's effect could be diminished when administered to individuals who are taking medicines that suppress the immune system. Separate injection sites must be used if more than one vaccine is being administered at the same time. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is given. Your doctor or nurse may still recommend that you receive Menveo if you are at high risk of infection with meningococcal group A, C, W-135 and Y bacteria. Driving and using machines Menveo is not likely to affect your ability to drive, cycle or use machines. However, do not drive, cycle or use any machines if you are not feeling well.
2
Menveo contains This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'. This medicinal product contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially 'potassium-free'. 3.
How to take it
Menveo
Menveo will be given to you or your child by a doctor or nurse. The vaccine is usually given into the upper arm muscle (deltoid) for children (from 2 years of age), adolescents and adults. Your doctor or nurse will take care to ensure the vaccine is not given into a blood vessel and will make sure that it is injected into muscle and not into the skin. For children (from 2 years of age), adolescents and adults: a single (0.5 mL) injection will be given. The safety and efficacy of Menveo in children under 2 years of age has not yet been established. There are limited data in individuals aged 56-65 and there are no data in subjects aged older than 65 years. Please tell your doctor if you have received a previous injection with Menveo or another meningococcal vaccine. Your doctor will tell you if you need an additional injection of Menveo. For information on the reconstitution of the vaccine see the section for medical or healthcare professionals at the end of this leaflet. If you have any further questions on the use of this medicine, ask your doctor or nurse. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common side effects reported during clinical studies usually lasted only one to two days and were not usually severe. The following side effects may happen after receiving Menveo: Very common (may affect more than 1 in 10 people): headache, muscle ache, irritability (in children from 2 to 10 years of age), generally feeling unwell, injection site pain, injection site redness (≤ 50 mm), injection site firmness (≤ 50 mm). Common (may affect up to 1 in 10 people): fever (≥ 38 °C), vomiting (in children from 2 to 10 years of age), diarrhoea (in children from 2 to 10 years of age), nausea, chills, change in eating habits (in children from 2 to 10 years of age), sleepiness (in children from 2 to 10 years of age), joint ache, rash, injection site redness (> 50 mm), injection site firmness (> 50 mm) Uncommon (may affect up to 1 in 100 people): allergic reactions, fainting, dizziness (in adolescents from 11 years of age and adults), balance disorder, enlarged lymph nodes, injection site itching, injection site swelling Very rare (may affect up to 1 in 10 000 people): fits (convulsions) including fits associated with fever, infection of the skin at the injection site, extensive swelling of the injected limb Not known (cannot be estimated from the available data): severe allergic reactions that manifest with the following symptoms: swelling of the lips, mouth, throat (which may cause difficulty in 3
swallowing), difficulty breathing with wheezing or coughing, rash and swelling of the hands, feet and ankles, loss of consciousness, very low blood pressure. If a severe allergic reaction occurs tell your doctor straight away or go immediately/ take your child to the nearest Accident and Emergency department because urgent medical help may be needed. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store 5.
How to store it
Menveo
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 C – 8 C). Do not freeze. Keep the vials in the outer carton in order to protect from light. After reconstitution, the product should be used immediately. However, chemical and physical stability after reconstitution was demonstrated for 8 hours below 25 °C. Do not throw away any medicines via wastewater or household waste. Your doctor or nurse will dispose of this medicine. These measures will help protect the environment. 6.
Contents of the pack and other information
What Menveo contains One dose (0.5 mL of the reconstituted vaccine) contains: The active substances are: (Originally contained in the powder) • Meningococcal group A oligosaccharide Conjugated to Corynebacterium diphtheriae CRM197 protein
10 micrograms 16.7 to 33.3 micrograms
(Originally contained in the solution) • Meningococcal group C oligosaccharide Conjugated to Corynebacterium diphtheriae CRM197 protein
5 micrograms 7.1 to 12.5 micrograms
• Meningococcal group W-135 oligosaccharide Conjugated to Corynebacterium diphtheriae CRM197 protein
5 micrograms 3.3 to 8.3 micrograms
• Meningococcal group Y oligosaccharide Conjugated to Corynebacterium diphtheriae CRM197 protein
5 micrograms 5.6 to 10.0 micrograms
The other ingredients (excipients) are: 4
In the powder: potassium dihydrogen phosphate and sucrose. In the solution: sodium chloride, sodium dihydrogen phosphate monohydrate, sodium hydrogen phosphate dihydrate and water for injection (See also end of section 2). What Menveo looks like and contents of the pack Menveo is a powder and a solution for injection. Each dose of Menveo is supplied as a: 1 Vial containing the MenA Lyophilised Conjugate Component as a white to off-white powder 1 Vial containing the MenCWY Liquid Conjugate Component as clear solution Pack size of one dose (2 vials), five doses (10 vials) or ten doses (20 vials). Not all pack sizes may be marketed. The contents of the two components (vial and vial) are to be mixed prior to vaccination providing 1 dose of 0.5 mL. Marketing Authorisation Holder GlaxoSmithKline UK Limited 79 New Oxford Street London WC1A 1DG United Kingdom Manufacturer GSK Vaccines S.r.l., Bellaria-Rosia, 53018 Sovicille (Siena), Italy Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK Only) Please be ready to give the following information: Product name Menveo powder and solution for solution for injection Reference number 19494/0289 This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in November 2025 Trademarks are owned by or licenced to the GSK group of companies. © 2025 GSK group of companies or its licensor —————————————————————————————————————–The following information is intended for healthcare professionals only: Reconstitution of the vaccine Menveo must be prepared for administration by reconstituting the powder with the solution. The contents in the two different vials (MenA powder and MenCWY solution) are to be mixed prior to vaccination providing 1 dose of 0.5 mL. Using a syringe and suitable needle (21G, 40 mm length or 21 G, 1 1⁄2 inch length), withdraw the entire contents of the vial of solution and inject into the vial of powder to reconstitute the MenA conjugate component. 5
Invert and shake the vial vigorously and then withdraw 0.5 mL of reconstituted product. Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose. Prior to injection, change the needle with one suitable for the administration. Ensure that no air bubbles are present in the syringe before injecting the vaccine. Following reconstitution, the vaccine is a clear, colourless to light yellow solution, free from visible foreign particles. In the event of any foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine. Menveo is given as an intramuscular injection, preferably into the deltoid muscle. Any unused product or waste material should be disposed of in accordance with local requirements.
6
Frequently asked questions about Menveo powder and solution for solution for injection
How do I take Menveo powder and solution for solution for injection?
Menveo powder and solution for solution for injection comes as injection. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Menveo powder and solution for solution for injection?
The active substance in Menveo powder and solution for solution for injection is meningococcal group a, c, w135 and y conjugate vaccine.
Are there equivalent medicines to Menveo powder and solution for solution for injection?
Medicines with the same active substance, strength and form include: MenQuadfi solution for injection, Menveo solution for injection. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Menveo powder and solution for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Menveo powder and solution for solution for injection without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: meningococcal group a, c, w135 and y conjugate vaccine
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease.
The use of this vaccine should be in accordance with official recommendations.
4.2. Posology and method of administration
Posology
Children (from 2 years of age), adolescents and adults
Menveo should be administered as a single dose (0.5 mL).
To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y. Bactericidal antibodies (hSBA ≥ 1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).
Older adults and elderly
There are limited data in older adults (aged 56-65 years) and there are no data in elderly (aged > 65 years).
Booster vaccination
Long-term antibody persistence data following vaccination with Menveo are available up to 5 years after vaccination (see section 4.4 and 5.1).
Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.
Paediatric population (under 2 years of age)
The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.
Method of administration
Menveo is given as an intramuscular injection, preferably into the deltoid muscle.
It must not be administered intravascularly, subcutaneously or intradermally.
Separate injection sites must be used if more than one vaccine is being administered at the same time.
For instructions on preparation and reconstitution of the medicinal product before administration, see section 6.6.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components (see section 4.4).
As with other vaccines, Menveo should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection is not a contraindication.
4.4. Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity and anaphylaxis
Before the injection of any vaccine, the person responsible for administration must take all precautions known for the prevention of allergic or any other reactions including thorough medical history and current health status. As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following administration of the vaccine.
Anxiety-related reactions
Anxiety‐related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection (see section 4.8). It is important that procedures are in place to avoid injury from fainting.
Menveo should under no circumstances be administered intravascularly.
Limitations of effectiveness
Menveo will not protect against infections caused by any other serogroups of N. meningitidis not present in the vaccine.
As with any vaccine, a protective immune response may not be elicited in all vaccinees (see section 5.1).
Studies with Menveo have shown a waning of serum bactericidal antibody titers against serogroup A when using human complement in the assay (hSBA) (see section 5.1). The clinical relevance of the waning of hSBA serogroup A antibody titers is unknown. If an individual is expected to be at particular risk of exposure to Men-A and received a dose of Menveo more than approximately one year previously, consideration may be given to administering a booster dose.
There are no data on the applicability of the vaccine for post-exposure prophylaxis.
Immunocompromised individuals
In immunocompromised individuals, vaccination may not result in an appropriate protective antibody response. While Human Immunodeficiency Virus (HIV) infection is not a contraindication, Menveo has not been specifically evaluated in immunocompromised people. Individuals with complement deficiencies and individuals with functional or anatomical asplenia may not mount an immune response to meningococcal group A, C, W-135 and Y conjugate vaccines.
Individuals with familial complement deficiencies (for example, C3 or C5 deficiencies) and individuals receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis group A, C, W-135 and Y, even if they develop antibodies following vaccination with Menveo.
Thrombocytopenia and coagulation disorders
Menveo has not been evaluated in persons with thrombocytopenia, bleeding disorders or that are receiving anticoagulant therapy, because of the risk of haematoma. The risk-benefit ratio for persons at risk of haematoma following intramuscular injection must be evaluated by health care professionals.
Excipients with known effects
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
Potassium
This medicinal product contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially 'potassium free'.
4.5. Interaction with other medicinal products and other forms of interaction
Menveo can be given concomitantly with any of the following vaccines: monovalent and combined hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, rabies and meningococcal group B (Bexsero).
In adolescents (11 to 18 years of age), Menveo has been evaluated in two co-administration studies with either Tetanus, Reduced Diphtheria and Acellular Pertussis Vaccine, adsorbed (Tdap) alone or Tdap and Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant (HPV), both of which support the co-administration of the vaccines.
The administration of Menveo one month after Tdap resulted in statistically significantly lower serogroup W-135 seroresponses. Since there was no direct impact on the seroprotection rate, the clinical consequences are presently unknown. There was evidence of some suppression of antibody response to two of the three pertussis antigens. The clinical relevance of this observation is unknown. After vaccination, over 97% of subjects had detectable pertussis titers to all three pertussis antigens.
For children 2 to 10 years of age, no data are available for evaluating safety and immunogenicity of other childhood vaccines when administered concomitantly with Menveo.
Concomitant administration of Menveo with vaccines other than those listed above has not been studied. Concomitant vaccines should always be administered at separate injection sites and preferably contralateral. It should be checked if the adverse reactions may be intensified by any co-administration.
If a vaccine recipient is undergoing immunosuppressant treatment, the immunological response may be diminished.
4.6. Fertility, pregnancy and lactation
Insufficient clinical data on exposed pregnancies are available.
In non-clinical studies, Menveo had no direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Considering the severity of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y, pregnancy should not preclude vaccination when the risk of exposure is clearly defined.
Although insufficient clinical data on the use of Menveo during breast-feeding are available, it is unlikely that secreted antibodies in milk would be harmful when ingested by a breastfed infant. Therefore, Menveo may be used during breast feeding.
4.7. Effects on ability to drive and use machines
Menveo has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4.8 “Undesirable effects” may temporarily affect the ability to drive or use machines.
4.8. Undesirable effects
Summary of the safety profile
The most frequently reported adverse reactions within 7 days after vaccination with a single dose of Menveo alone in individuals aged 2 years and above were injection-site pain (42.7%), headache (26.4%), injection-site erythema ≤ 50 mm (18.1%), malaise (17.3%), injection-site induration ≤ 50 mm (15.1%), myalgia (13.5%), and irritability (11.3%) in children aged 2 to 10 years. These adverse reactions were mostly mild or moderate in intensity.
Tabulated list of adverse reactions
The safety of Menveo in individuals aged 2 years and older was evaluated in 11 randomized studies. 12 775 individuals were included in the safety analyses. Of these, 3 334 participants aged 2 to 10 years and 9 441 participants aged 11 to 65 years were exposed to Menveo in completed clinical studies.
The following adverse reactions, as listed in Table 1 below, have been identified in clinical studies conducted with Menveo when given to individuals aged 2 years and older, and during post-marketing surveillance.
Adverse reactions are listed below by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common
Common
Uncommon
Rare
Very rare
Not known
(≥ 1/10)
(≥ 1/100 to < 1/10)
(≥ 1/1 000 to < 1/100)
(≥ 1/10 000 to < 1/1 000)
(< 1/10 000)
(cannot be estimated from the available data)
Table 1: Adverse reactions
System organ class
Frequency
Adverse reactions
Blood and lymphatic system disorders
Uncommon
Lymphadenopathy1
Immune system disorders
Uncommon
Hypersensitivity1
Not known
Anaphylaxis1
Metabolism and nutrition disorders
Common
Eating disorder2
Nervous system disorders
Very common
Headache
Common
Sleepiness2
Uncommon
Syncope1, dizziness3
Very rare
Tonic convulsion1, febrile convulsion1
Ear and labyrinth disorders
Uncommon
Vertigo1
Gastrointestinal disorders
Common
Vomiting2, diarrhoea2, nausea
Skin and subcutaneous tissue disorders
Common
Rash
Musculoskeletal and connective tissue disorders
Very common
Myalgia
Common
Arthralgia
General disorders and administration site conditions
Very common
Irritability2, malaise, injection site pain, injection site erythema (≤ 50 mm), injection site induration (≤ 50 mm)
Common
Fever (≥38 °C), chills, injection site erythema (> 50 mm), injection site induration (> 50 mm)
Uncommon
Injection site pruritus, injection site swelling1
Very rare
Injection site cellulitis1, extensive swelling of the injected limb1
1 Adverse reaction reported during post-marketing surveillance
2 Reported in children 2 to 10 years of age
3 Reported in individuals 11 to 65 years of age
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Medicines and Healthcare products Regulatory Agency (MHRA) at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
No case of overdose has been reported.
💬 Ask about this leaflet
Ask anything about Menveo powder and solution for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.